Randall Moreadith, MD, Ph.D.
President and Chief Executive Officer

Randall Moreadith joined Serina Therapeutics in September 2010 as Chief Executive Officer. Prior to joining Serina, Dr. Moreadith, 56, was Chief Development Officer at Nektar Therapeutics where he built a clinical and drug development program that successfully moved several of the company's PEGylated small molecule drugs into the clinic, including the launch of NKTR-102 into four clinical indications (ovarian, breast, cervical and colorectal cancer). He was formerly the Executive Vice President and Chief Medical Officer of Cardium Therapeutics where he led the advancement of novel DNA-based therapeutics into Phase 2b and Phase 3 late-stage development. Before Cardium, Dr. Moreadith served as Chief Medical Officer of Renovis, Inc. where he led the Clinical, Regulatory and Quality Assurance Groups. Prior to that, Dr. Moreadith was co-Founder, President and Chief Operating Officer of ThromboGenics Ltd., a leader in the field of thrombosis drug development. During his tenure at ThromboGenics, the company advanced four biologics into mid-stage development. Dr. Moreadith began his career in the pharmaceutical industry as Principal Medical Officer of Quintiles, Inc., the world's leading pharmaceutical services organization, where he led the Cardiovascular Therapeutics Group.

Dr. Moreadith has published more than 50 scientific papers and multiple book chapters, is an inventor on four patents and has received numerous awards for his achievements. He received his M.D. from Duke University and is trained clinically in Internal Medicine and Cardiovascular Diseases. He received his Ph.D. from Johns Hopkins University, and following his Fellowship in Cardiology at Duke University he joined the laboratory of Professor Philip Leder where he was a Howard Hughes Medical Institute Fellow in Genetics at Harvard Medical School. Dr. Moreadith was a member of the faculty of the University of Texas Southwestern Medical Center, where he was an Established Investigator of the American Heart Association.

Michael Bentley, PhD
Founder, Chief Scientific Officer

Dr. Bentley received his B.S. (1963) and M.S. (1965) degrees in Chemistry from Auburn University, his Ph.D. in Organic Chemistry from the University of Texas in Austin in 1968, and did postdoctoral work at the University of California, Berkeley in 1968-9. Dr. Bentley was Professor and Chair of Chemistry at the University of Maine and won the Presidential Research and Creative Achievement Award at the University. He joined Shearwater Corporation in 1997 to head its research group and begin a drug development program there. Prior to this time Shearwater had focused on supply of PEG reagents to pharmaceutical companies. Dr. Bentley utilized Shearwater's polyethylene glycol chemistry to create several new platforms for the enhancement and enablement of PEG-small molecule pharmaceutical conjugates for sustained drug delivery and for membrane barrier exclusion. This technology now forms the basis of multiple products in human clinical trials at Nektar, including for the treatment of cancer and opioid-induced constipation. The latter product was recently licensed to AstraZeneca in a billion-dollar deal. Dr. Bentley has numerous patents and publications in several areas of chemistry. Dr. Bentley has been a Fulbright Senior Research Scholar and a Fellow of the Japan Agency for Science and Technology.

Tacey Viegas, Ph.D.
Chief Operating Officer

Dr. Viegas received his B.S. in Chemistry (1977) and Pharmacy (1981) from Bangalore University, his M.S. (1984) and Ph.D. (1988) in Pharmaceutical Sciences from the University of Mississippi. He worked at R.P. Scherer Corporation (now Catalent), MDV Technologies, BioCryst Pharmaceuticals and Shearwater Corporation (now Nektar Therapeutics). He has 22 years of pharmaceutical industrial experience in drug discovery, drug delivery and pharmacokinetics. Dr. Viegas has managed the discovery and early development activities for both synthetically- and biologically-derived therapeutic agents in the areas of oncology, pain, influenza, psoriasis and wound care. He has numerous patents and publications in the area of polymer therapeutics and pharmaceutics, and he also received the American College of Clinical Pharmacology award for his presentation on the clinical applications of purine nucleosides.